NCT00325936 is a Phase 4 clinical trial of Cilnidipine in Hypertension, sponsored by Boryung Pharmaceutical Co., Ltd.

Who is sponsoring NCT00325936?

NCT00325936 is sponsored by Boryung Pharmaceutical Co., Ltd.

What drugs are being tested in NCT00325936?

Interventions in NCT00325936: Cilnidipine.

What condition does NCT00325936 study?

NCT00325936 studies Hypertension, Metabolic Syndrome X.

Is NCT00325936 still recruiting?

NCT00325936 is currently completed. Last updated 26 August 2008.

Last reviewed 2008-08-26 · How we verify

NCT00325936

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]

Completed Phase 4 Last updated 26 August 2008

What this trial tests

Phase 4 trial testing Cilnidipine in Hypertension in 186 participants. Completed in 1 June 2007.

Timeline

1 July 2005

Primary endpoint
1 June 2007

1 June 2007

Quick facts

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	186
Start date	1 July 2005
Primary completion	1 June 2007
Estimated completion	1 June 2007
Sites	1 location across South Korea

Drugs / interventions tested

Cilnidipine (CILNIDIPINE) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →
Metabolic Syndrome X — all drugs for Metabolic Syndrome X →

Sponsor

Boryung Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 30 to 65, any sex, with Hypertension or Metabolic Syndrome X. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Homeostasis model assessment of insulin sensitivity (HOMA-IR)
Time frame: after 3 month and 12 month treatment
Triglyceride/HDL cholesterol ratio
Time frame: after 3 month and 12 month treatment

Sponsor's own description

Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance. Therefore, whenever treating such patients, antihypertensive agents that may have the added effect of improving insulin resistance should be selected. CinalongTM (Cilnidipine) is expected to improve metabolic syndrome as well as insulin resistance by its dual effects on L and N-type calcium (Ca) channels. In this study, the researchers investigate the effects of CinalongTM on insulin resistance and other metabolic related factors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Boryung Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07421414 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421401 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421388 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07421375 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
NCT07373613 — A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00325936 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boryung Pharmaceutical Co., Ltd
Last refreshed: 26 August 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00325936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing